cefotaxime and Prostatic-Hyperplasia

In a prospective randomized study of 192 patients, the effect of a short course of cefotaxime in connection with transurethral prostatic resection was analyzed. The antibiotic was given to 98 patients, while 94 were assigned to a control group without antibiotic. The frequency of bacteriuria in the cefotaxime group was 43% preoperatively and 18% six weeks postoperatively. In the control group the corresponding figures were 40 and 42% (p less than 0.01). Complicated postoperative infection did not occur in the cefotaxime group, but in the control group there was one case of septicemia and seven patients had upper urinary tract infections (p less than 0.01). In the cefotaxime group, patients with preoperatively negative urine culture were prevented from acquiring bacteriuria, and 67% of preoperatively present infections were eliminated at six weeks after the operation, as compared with 30% in the control group. There were essentially no side effects of cefotaxime. Renal function was not influenced by the combination of cefotaxime and furosemide.

Topics: Aged; Bacterial Infections; Bacteriuria; Cefotaxime; Drug Evaluation; Humans; Male; Middle Aged; Postoperative Complications; Premedication; Prostatectomy; Prostatic Hyperplasia; Urinary Tract Infections

Forty-two men with urinary tract infection and benign prostatic hyperplasia were randomized into two groups before transurethral resection. One group (22 patients) received Claforan (cefotaxime) peroperatively and thereafter daily for five days. In the other group (20 patients), Hiprex (methenamine hippurate) was given daily from the day before the operation, for a total of six days. All the bacterial isolates were sensitive to cefotaxime. The efficacy of the medication was clinically and bacteriologically evaluated. Postoperative temperature elevation (greater than 38 degrees C) occurred in one of the 22 patients in the cefotaxime group, and in nine of the 20 in the methenamine hippurate group (p less than 0.05). None of the former group, but two patients in the latter, had septicemia. The difference was not statistically significant. The response to treatment was satisfactory in 13 of the 22 patients in the cefotaxime group, but in only one of the 20 treated with methenamine hippurate (p less than 0.005). Antibiotic treatment is recommended for bacteriuric patients undergoing transurethral prostatic resection.

Topics: Aged; Cefotaxime; Clinical Trials as Topic; Hippurates; Humans; Male; Methenamine; Middle Aged; Postoperative Complications; Premedication; Prostatectomy; Prostatic Hyperplasia; Random Allocation; Sepsis; Urethra; Urinary Tract Infections

Twenty-four patients suffering from prostate hyperplasia were given venous injections of CDZM of either 1 or 2 g at specific intervals (30 min, 1, 2 and 4 hr) before surgery. Blood samples from the injected vein and tissue samples from the prostate were subsequently taken. In this study, the concentrations of CDZM in the prostate tissue (P) and in serum (S), as well as the ratio of the tissue to serum concentrations (P/S) were determined. In patients given 1 g injections, P ranged from 5.26-48.10 micrograms/g, while S ranged from 25.40-130.00 micrograms/ml and P/S ranged from 12.6-37.0%. In the patients given 2 g injections, P ranged from 9.40-49.20 micrograms/g, S ranged from 62.30-234.00 micrograms/ml and P/S ranged from 9.3-29.1%. CDZM exhibited excellent transmigration to the prostate tissue. Inflammatory bacteria present in prostatitis and urinary tract infections are generally those of E. coli, Proteus sp., but because the P range was much higher than the ratio of MIC, CDZM is expected to be useful against infections in the field of urology.

Topics: Aged; Aged, 80 and over; Cefotaxime; Humans; Male; Prostate; Prostatic Hyperplasia

The penetration of Cefixime (CFIX) into the prostatic tissue and the serum was examined in 54 patients with benign prostatic hypertrophy treated with transurethral resection of the prostate. CFIX was administered orally in a dose of 200 mg 2 times daily for 3 days preoperatively. The blood samples were taken at the time of the tissue sampling. The patients were divided into 2 groups. In group 1 (16 patients), the tissue sampling was done about 17 hours after the final drug administration. The mean concentration of CFIX was 0.83 +/- 0.49 micrograms/g in the prostatic tissue and 0.84 +/- 0.63 micrograms/ml in the serum. In the prostatic tissue, CFIX was detected in only 4 patients, in the other 12 patients, CFIX was not detected. In group 2 (38 patients), tissue sampling was done 5.5 hours after the final drug administration. The mean concentration of CFIX was 1.08 +/- 0.47 micrograms/g in the prostatic tissue and 3.18 +/- 1.28 micrograms/ml in the serum.

Topics: Administration, Oral; Aged; Aged, 80 and over; Cefixime; Cefotaxime; Humans; Male; Middle Aged; Prostate; Prostatectomy; Prostatic Hyperplasia

Although Cephem antibiotics are transferred to the prostatic fluid in relatively low levels, they are clinically effective for bacterial prostatitis. In the present study, the prostatic tissue concentration of Latamoxef (LMOX), Cefoperazone (CPZ) and Cefotaxime (CTX) were determined, and their penetration rates into the prostatic tissue were analyzed. Before the transurethral resection of the prostate (TUR-P), 2 g of LMOX (21 patients), 1 g of CPZ (15 patients) and 2 g of CTX (14 patients) were intravenously administered in a total of 50 patients with benign prostatic hypertrophy at our two Hospitals. The prostatic tissue was taken by TUR-P at 30 minutes and 60 minutes after the injection. The serum concentration and the prostatic tissue concentration of the three antibiotics were determined by the bioassay method. Additionally their serum concentration and the prostatic tissue concentration in the six cases of CTX-injected patients were also determined by high performance liquid chromatography (HPLC). The penetration rate into the prostatic tissue was obtained by the formula; the penetration rate = the prostatic tissue concentration/the serum concentration. The prostatic tissue concentrations determined by the bioassay method were, 36.9 +/- 10.6 micrograms/g at 30 minutes after the injection of 2 g of LMOX and 28.0 +/- 9.0 micrograms/g at 60 minutes, 31.0 +/- 8.3 micrograms/g at 30 minutes after the injection of 1 g of CPZ and 21.1 +/- 10.0 micrograms/g at 60 minutes, and 8.8 +/- 4.1 micrograms/g at 30 minutes after the injection of 2 g of CTX and 4.5 +/- 2.0 micrograms/g at 60 minutes (mean +/- S.D.). The penetration rates determined by the bioassay method were 36.2 +/- 10.9% at 30 minutes after the injection of LMOX and 34.8 +/- 15.3% at 60 minutes, 43.6 +/- 14.4% at 30 minutes after the injection of CPZ and 39.7 +/- 24.1% at 60 minutes, and 11.1 +/- 4.1% at 30 minutes after the injection of CTX and 9.6 +/- 3.8% at 60 minutes (mean +/- S.D.). The penetration rate of CPZ and LMOX were significantly higher than that of CTX (P less than 0.05, P less than 0.01). In 6 of the 14 CTX-injected patients, the serum and prostatic tissue concentrations of CTX and its metabolite, desacetyl-CTX, were also determined by HPLC. The penetration rate of CTX into the prostatic tissue was obtained by the formula; the penetration rate of CTX = the prostatic tissue concentration (CTX + Desacetyl-CTX)/the serum concentration (CTX + Desacetyl-CTX).(ABSTRACT TRUNCATED AT 400 WO

Topics: Aged; Aged, 80 and over; Biological Transport; Cefoperazone; Cefotaxime; Chromatography, High Pressure Liquid; Humans; Male; Middle Aged; Moxalactam; Premedication; Prostate; Prostatectomy; Prostatic Hyperplasia

The concentrations of Cefmenoxime (CMX) were examined in the serum and prostatic tissue of 25 patients with benign prostatic hypertrophy and of 1 patient with prostatic carcinoma. The CMX levels were measured at scheduled intervals after 2 g CMX administration by one hour drip infusion prior to prostatectomy. Pharmacokinetic analysis was performed based on the two compartment open model theory. 1) Maximum serum level of CMX was 124 micrograms/ml at the end of drip infusion and the biological half-life was 1.07 hrs. 2) CMX concentration in prostatic tissue reached a maximum level of 35.7 cg/g at 1.16 hrs after the start of CMX administration. Ratio of prostatic tissue to serum level in the area under curve (AUC) was 33% and biological half-life was 1.07 hrs. These results suggested that the CMX concentration in the prostatic tissue was higher than the MIC80 against pathogenic bacteria, particularly E.coli and Klebsiella sp. for a relatively long time. For this reason CMX is one of the more preferred drugs for treatment of chronic prostatitis and post-operative infection of prostate.

Topics: Aged; Cefmenoxime; Cefotaxime; Humans; Infusions, Parenteral; Kinetics; Male; Middle Aged; Models, Biological; Prostate; Prostatic Hyperplasia

Serum and prostatic tissue levels of Ceftizoxime (CZX) were measured in 37 patients with benign prostatic hypertrophy after intravenous infusion of 0.5 g or 1 g or 2 g of CZX. The prostatic tissue level of CZX was sufficient for the treatment of prostatic infection. Serum and prostatic tissue levels of CZX were maintained satisfactorily by the dose of CZX. Neither the weight of extracted prostatic tissue nor the renal function of the patient was correlated to the tissue level of CZX.

Topics: Cefotaxime; Ceftizoxime; Humans; Infusions, Parenteral; Male; Prostate; Prostatic Hyperplasia

One gram of ceftizoxime (CZX) was administrated before transurethral resection in 38 cases of benign prostatic hypertrophy. Then the serum and tissue concentration of CZX was measured, and compared with the sensitivity of CZX to the bacteria separated from the urine of inpatients. The concentration of CZX in prostatic tissue was higher than the MIC80 for E. coli for 16.7 hr, for Klebsiella for 18.7 hr, for Proteus for 14.7 hr and for Serratia for 8.86 hr. Therefore, CZX was considered to be an effective drug against bacterial prostatitis.

Topics: Aged; Bacteria; Cefotaxime; Ceftizoxime; Drug Resistance, Microbial; Humans; Injections, Intravenous; Male; Middle Aged; Prostate; Prostatic Hyperplasia; Prostatitis; Urine

Prostatic tissue levels and serum levels of Ceftizoxime (CZX), Cefoperazone (CPZ) and Cefotaxime (CTX), after intravenous administration were studied in 82 patients with prostatic hypertrophy, who underwent transurethral surgery. CZX was found to be the most effective for treatment of prostatic infection, since its prostatic tissue level was considerably higher than the others, satisfactorily above the MIC level of most bacteria. The prostatic tissue levels were not correlated with prostate size. The levels in fibromuscular hyperplasia were significantly higher than in glandular hyperplasia.

Topics: Aged; Cefoperazone; Cefotaxime; Ceftizoxime; Humans; Male; Prostate; Prostatic Hyperplasia

A total of 46 patients aged 59-84 who underwent transurethral resection of the prostate gland received 2 g of ceftriaxone intravenously at different points in time, ranging from 30 min to 74 h before the operation. The antibiotic concentration was determined in the serum as well as in the prostate adenoma tissue using microbiological methods after treating the tissue in a stomacher. 30 min after application, tissue concentrations were between 12.9 and 73.7 micrograms/g, and after 4 h still between 1.0 and 50.0 micrograms/g. Even after 48 h levels between 0.6 and 5.6 micrograms/g were found. Therefore ceftriaxone proved not only to have a long serum half-life as compared to other comparable cephalosporins, but also prolonged tissue concentrations, which justifies a single preoperative dose before transurethral resection of the prostate gland, as established by the clinical results described.

Topics: Aged; Biological Assay; Cefotaxime; Ceftriaxone; Half-Life; Humans; Injections, Intravenous; Male; Middle Aged; Prostatic Hyperplasia

Topics: Bacteriuria; Cefotaxime; Epididymitis; Humans; Male; Postoperative Complications; Prostatectomy; Prostatic Hyperplasia; Prostatic Neoplasms; Sepsis; Urinary Tract Infections

Prostatic and vesical tissue levels of Ceftizoxime (CZX) were determined in 21 patients with prostatic hyperplasia after the intravenous administration of 1 g of CZX. Serum concentration on prostatic surgery continued to be 1.3 fold higher than that of healthy adults. Prostatic tissue levels attained a peak of 40.7 +/- 1.6 micrograms/g (mean +/- SE) at 30 minutes after administration and vesical tissue levels attained a peak of 72.4 +/- 24.8 micrograms/g at 30 minutes. The mean value was 21.0 +/- 6.4 micrograms/g in prostatic tissue after administration for 120 minutes with the tissue/serum ratio of 0.91. Prostatic tissue level in glandular dominant were slightly higher than those of myoglandular hyperplasia (P less than 0.1). Judging from its favorable transfer into the prostatic tissue and MIC against clinically isolated E. coli, Proteus sp. and Klebsiella, CZX seemed to be clinically useful in the treatment of prostatic infection.

Topics: Aged; Biological Transport; Cefotaxime; Ceftizoxime; Humans; Injections, Intravenous; Male; Middle Aged; Prostate; Prostatic Hyperplasia; Time Factors; Urinary Bladder

Concentrations of cefotaxime (CTX) in serum and prostatic tissue were studied in human and rat. CTX kept high level of 40 to 100 micrograms/g in prostatic tissue at least as long as 2 hours following intraperitoneal injection in a dosis of 100 mg/kg of body weight in rat. Patients intravenously injected of 1 g of CTX showed the activity of 6.8 +/- 4.1 micrograms/g in prostatic tissue.

Topics: Aged; Animals; Cefotaxime; Humans; Injections, Intravenous; Male; Middle Aged; Prostate; Prostatic Hyperplasia; Rats; Rats, Inbred Strains